Plus Therapeutics, Inc. (NASDAQ:PSTV – Free Report) – Investment analysts at HC Wainwright issued their FY2029 earnings estimates for Plus Therapeutics in a research report issued to clients and investors on Friday, March 28th. HC Wainwright analyst S. Lee forecasts that the company will earn $0.95 per share for the year. HC Wainwright has a “Buy” rating and a $5.50 price target on the stock. The consensus estimate for Plus Therapeutics’ current full-year earnings is ($2.30) per share.
Several other equities research analysts also recently commented on the company. D. Boral Capital restated a “buy” rating and set a $9.00 price objective on shares of Plus Therapeutics in a report on Friday. Ascendiant Capital Markets reduced their price target on shares of Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating for the company in a research report on Monday, December 9th.
Plus Therapeutics Stock Performance
PSTV stock opened at $1.16 on Monday. The stock’s 50 day simple moving average is $1.11 and its 200 day simple moving average is $1.24. The company has a market cap of $6.84 million, a P/E ratio of -0.46 and a beta of 0.73. Plus Therapeutics has a fifty-two week low of $0.24 and a fifty-two week high of $2.67.
Plus Therapeutics (NASDAQ:PSTV – Get Free Report) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16). The firm had revenue of $1.80 million for the quarter, compared to the consensus estimate of $1.19 million.
About Plus Therapeutics
Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Further Reading
- Five stocks we like better than Plus Therapeutics
- What Does Downgrade Mean in Investing?
- Venezuelan Tariffs Could Power These 3 Diesel-Driven Winners
- How to Use High Beta Stocks to Maximize Your Investing Profits
- MarketBeat Week in Review – 03/24 – 03/28
- Stock Market Sectors: What Are They and How Many Are There?
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
